Loading...
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie, P Marshall, A Dunn, J Middleton, M Nathan, P Gore, M Davidson, N Nicholson, S Kelly, C Marples, M
Corrie, P
Marshall, A
Dunn, J
Middleton, M
Nathan, P
Gore, M
Davidson, N
Nicholson, S
Kelly, C
Marples, M
Citations
Altmetric:
Abstract
Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis.
Description
Date
2014-05
Publisher
Collections
Keywords
Type
Article
Citation
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. 2014, 15 (6):620-30 Lancet Oncol